glp 1 for cardiovascular health The effects of GLP-1 receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action Glucagon-like peptide 1 receptor agonists:

GLP-1 medications such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are transforming lives

Low levels are associated with liver dysfunction, immune dysfunction, cardiac disease, premature aging

But one common question still remains when should you actually take it

A recent clinical trial found that people living with cardiovascular disease had a major reduction in heart attacks, stroke and other cardiovascular disease events after taking semaglutide continuously for four years

J Appl Pharm Sci 2011:110 Karagiannis ED, Popel AS (2008) Novel anti-angiogenic peptides derived From ELR-containing CXC chemokines